Incorrect password
evipedia.ai Suggest Edit

Fisetin for Health & Longevity

Evidence Review created on 05/03/2026 using AI4L / Opus 4.7

Also known as: 3,3’,4’,7-Tetrahydroxyflavone, Cognisetin, Novusetin

Motivation

Fisetin is a naturally occurring plant flavonol found in small amounts in strawberries, apples, persimmons, and other fruits and vegetables. Within the longevity community, it is best known as a candidate senolytic — a compound thought to selectively clear damaged, non-dividing senescent cells that accumulate with age and drive chronic inflammation and tissue decline.

Interest accelerated after a single-laboratory mouse study reported that intermittent late-life fisetin treatment cleared senescent cells across multiple tissues and extended lifespan. A subsequent multi-site replication in genetically diverse mice did not confirm the lifespan effect, and human clinical evidence remains thin. Controlled trials at several academic centers, including the Mayo Clinic, are now in progress.

This review examines what fisetin is, how it is thought to act, the strength of the preclinical and emerging human evidence on its proposed benefits, the practical risks, and the protocols used by the research groups who study it most closely.

Benefits - Risks - Protocol - Conclusion

This section lists high-level overviews and expert commentary on fisetin suitable for orientation before reading the rest of the document.

  • Fisetin inhibits senescence and slows down aging - Rhonda Patrick

    Science Digest entry covering the landmark 2018 EBioMedicine study identifying fisetin as the most potent senolytic among ten flavonoids screened, with discussion of senescent-cell clearance and lifespan extension in aged mice.

  • Longevity Drugs, Aging Biomarkers, and Updated Findings from the Interventions Testing Program - Peter Attia

    The Drive episode #281 with Rich Miller, director of the National Institute on Aging Interventions Testing Program (ITP), reviewing the multi-site results showing fisetin did not significantly extend lifespan in genetically heterogeneous mice — essential counterpoint to the original single-laboratory findings.

  • Fisetin: A Senolytic That Extends Life - Charles Wyatt

    Magazine article reviewing fisetin’s senolytic mechanisms, the preclinical evidence for lifespan extension, the development of bioavailability-enhanced formulations using fenugreek-derived galactomannans, and preliminary clinical evidence from stroke and colorectal cancer trials. Conflict of interest: Life Extension is a commercial vendor that sells branded fisetin products (Bio-Fisetin), so its editorial conclusions favorable to fisetin overlap with its direct commercial interest.

  • Fisetin Is a Senotherapeutic That Extends Health and Lifespan - Yousefzadeh et al., 2018

    The original preclinical paper from Mayo Clinic and Scripps Research that screened ten flavonoids for senolytic activity, identified fisetin as the most potent, and reported reduced senescence markers and extended lifespan in aged wild-type mice receiving intermittent late-life dosing. Conflict of interest: Mayo Clinic and the Salk Institute hold senolytic-related intellectual property and run the principal Phase 2 fisetin trials, giving these institutions a direct financial and reputational interest in fisetin’s positive characterization.

  • Fisetin & Your Brain - Alzheimer’s Drug Discovery Foundation

    Evidence summary from the ADDF’s Cognitive Vitality program covering fisetin’s antioxidant, anti-inflammatory, and synaptic-plasticity mechanisms, preclinical evidence in Alzheimer’s models, the bioavailability problem, and the safety profile.

Note: No dedicated long-form content on fisetin was identified from Andrew Huberman or Chris Kresser; both have referenced the compound only briefly within broader discussions of polyphenols and senolytics.

Grokipedia

  • Fisetin

    A reference-style page covering chemistry (the flavonol 3,3’,4’,7-tetrahydroxyflavone, formula C15H10O6), dietary sources, antioxidant and anti-inflammatory activity, neuroprotective effects, anticancer mechanisms, and the emerging senolytic role for selectively eliminating senescent cells.

Examine

No dedicated Examine.com supplement page for fisetin exists as of 05/03/2026. Examine.com references fisetin only inside research-feed entries on related compounds and broader flavonoid topics.

ConsumerLab

No dedicated ConsumerLab.com supplement-testing page for fisetin exists as of 05/03/2026. ConsumerLab references fisetin only within Q&A/answers entries, not as a standalone supplement-testing review.

Systematic Reviews

A summary of systematic reviews evaluating fisetin from PubMed.

Mechanism of Action

Fisetin is a small lipophilic flavonol whose biological effects derive from convergent activity at several pathways relevant to aging.

  • Senolytic activity: Fisetin selectively induces apoptosis (programmed cell death) in senescent cells, the persistent non-dividing cells that accumulate with age and secrete pro-inflammatory factors. In a comparative screen of ten flavonoids, fisetin was the most effective at clearing senescent fibroblasts and behaved as a “hit-and-run” agent — short, intermittent exposure produced lasting reductions in senescent-cell burden without continuous dosing.

  • Antioxidant defense via Nrf2: Fisetin directly scavenges reactive oxygen species and activates the Nrf2-ARE pathway (Nrf2 is a transcription factor that turns on antioxidant and detoxification genes). This raises levels of reduced glutathione, superoxide dismutase, and catalase.

  • Anti-inflammatory signaling via NF-κB: Fisetin inhibits NF-κB (nuclear factor kappa B, a master regulator of inflammatory gene expression) and reduces output of pro-inflammatory cytokines including TNF-α (tumor necrosis factor alpha, a key inflammatory signaling molecule), IL-1β (interleukin-1 beta), IL-6, and IL-8. It also suppresses COX-2 (cyclooxygenase-2, an enzyme that produces inflammatory prostaglandins) and inducible nitric oxide synthase.

  • SIRT1 activation: Fisetin activates SIRT1 (sirtuin 1, a NAD+-dependent enzyme involved in metabolic regulation, stress resistance, and longevity-related signaling), which feeds into autophagy and mitochondrial biogenesis programs.

  • Neuroprotection and synaptic plasticity: Fisetin enhances long-term potentiation (the cellular substrate of memory) by activating Ras-ERK (a growth-factor signaling cascade) and CREB (a transcription factor involved in memory consolidation), preserves mitochondrial function in neurons under oxidative stress, and inhibits 5-lipoxygenase (an enzyme that produces pro-inflammatory leukotrienes).

  • Anticancer signaling: In tumor cells, fisetin engages both intrinsic (mitochondrial) and extrinsic (death-receptor) apoptosis pathways, induces cell-cycle arrest, suppresses angiogenesis, and downregulates matrix metalloproteinases involved in invasion and metastasis.

A 2025 hormesis review (Calabrese et al., Biogerontology) argues that many of fisetin’s chemoprotective effects follow a biphasic dose-response curve, with low doses producing benefits and high doses losing or reversing them — a competing mechanistic framing relevant to dose selection.

Pharmacological properties: Fisetin is a polyphenol, not a registered pharmaceutical. Its plasma half-life after oral dosing of unformulated fisetin is short, on the order of 1–2 hours, with extensive first-pass glucuronidation and sulfation by phase II enzymes (UGT1A and SULT family members). It is widely distributed across tissues including brain, where it crosses the blood-brain barrier. It is a potent in vitro inhibitor of CYP2C9 (a liver enzyme that metabolizes warfarin and several other drugs) and CYP2C19 (a liver enzyme that activates clopidogrel and metabolizes proton-pump inhibitors). Bioavailability-enhanced formulations using fenugreek galactomannans or liposomal carriers have been reported to extend exposure substantially.

Historical Context & Evolution

Fisetin was first isolated in the 19th century from the smoke tree (Cotinus coggygria), historically used as a yellow textile dye. For most of the 20th century, it was studied only as a minor dietary flavonol with modest antioxidant activity.

Two research lines transformed its profile. Beginning in the mid-2000s, Pamela Maher and colleagues at the Salk Institute identified fisetin as a neuroprotective agent that enhanced memory in mice and protected against several neurodegenerative-disease models; the Salk Institute holds a patent on fisetin as a memory enhancer. In 2018, Yousefzadeh and colleagues at the Mayo Clinic and Scripps Research reported that, among ten flavonoids screened for senolytic activity, fisetin was the most potent, and that intermittent late-life fisetin treatment in aged wild-type mice reduced senescence markers across multiple tissues and extended median and maximum lifespan.

The narrative became more complex in 2024 when the Interventions Testing Program (ITP) — a multi-site, genetically heterogeneous mouse-lifespan program funded by the National Institute on Aging and considered the gold standard for replicating longevity findings — reported that fisetin did not significantly affect lifespan in either sex at the dose and schedule tested (Harrison et al., GeroScience, 2024). The findings of the original Yousefzadeh and the ITP work are not necessarily contradictory; differences in dose, timing, formulation, and mouse genetic background may all contribute, and reconciling them is now an active area of research. Multiple human trials, mostly Phase 2, have been launched in the wake of the 2018 paper to test whether senolytic effects translate into clinical benefit.

Expected Benefits

A dedicated literature search across published trials, systematic reviews, and clinical-trial registries was performed to assemble a complete benefit profile for fisetin before drafting this section, with framing oriented toward health- and longevity-focused adults rather than population averages.

Medium 🟩 🟩

Senescent-Cell Clearance ⚠️ Conflicted

In the 2018 Yousefzadeh study, intermittent oral fisetin in aged wild-type mice reduced p16 (a cyclin-dependent kinase inhibitor whose expression marks senescent cells) and p21 (another cyclin-dependent kinase inhibitor associated with senescence) senescence markers and senescence-associated secretory phenotype (SASP) factors in adipose, kidney, liver, and spleen, and reduced senescent-cell markers in human adipose-tissue explants ex vivo. A 2020 Mayo Clinic open-label pilot in older adults reported reduction in circulating senescence-associated markers after a 2-day high-dose protocol. However, the multi-site ITP did not reproduce a lifespan benefit in genetically heterogeneous mice, and several Mayo Clinic Phase 2 trials in frailty, osteoarthritis, and skeletal health have completed enrollment but have not yet published primary efficacy results in peer-reviewed journals as of January 2026. The translation of clearance effects to durable functional or longevity outcomes in humans is therefore uncertain and actively contested.

Magnitude: Approximately 10% extension of median lifespan in the original aged-mouse study; no significant lifespan effect in the multi-site ITP. Human senescent-cell-marker reductions reported in pilot work but not yet quantified across rigorously controlled phase 2 trials.

Anti-Inflammatory Effect

In a published double-blind randomized controlled trial (RCT) of 37 colorectal-cancer patients receiving chemotherapy, 100 mg/day fisetin for seven weeks significantly reduced plasma interleukin-8 versus placebo and reduced high-sensitivity C-reactive protein and matrix metalloproteinase-7 within the fisetin group. Preclinical work consistently shows suppression of NF-κB signaling and several pro-inflammatory cytokines. Inflammation is mechanistically central to age-related disease, so even modest anti-inflammatory effects are relevant for the longevity-oriented audience, though the human evidence base remains small.

Magnitude: Statistically significant reduction in plasma interleukin-8 versus placebo in one small RCT (n=37); within-group reductions in C-reactive protein in the same trial that did not reach significance versus placebo.

Adjunctive Neurological Recovery After Ischemic Stroke

A double-blind randomized controlled trial in 192 ischemic-stroke patients reported that 100 mg/day fisetin combined with intravenous tissue plasminogen activator (the standard clot-dissolving therapy for stroke) significantly improved National Institutes of Health Stroke Scale scores in patients treated 3–5 hours after symptom onset, effectively widening the therapeutic window. The benefit was associated with reductions in serum matrix metalloproteinase-2 and -9 and C-reactive protein. This is a narrow but well-defined acute-care indication; relevance to general longevity supplementation is indirect.

Magnitude: Significant improvement in stroke-severity scores at the 3–5 hour treatment window in one RCT (n=192); no detectable benefit at the 0–3 hour window.

Low 🟩

Bone and Joint Protection

A systematic review of 13 preclinical studies found that fisetin inhibits osteoclast differentiation (cells that break down bone), supports osteoblast activity (cells that build bone), and reduces cartilage-degradation markers in osteoarthritis models. A small completed trial in human knee osteoarthritis (NCT04210986) and a Mayo-affiliated skeletal-health trial in older adults (NCT04313634) have completed but full peer-reviewed efficacy publications are not yet available.

Magnitude: Not quantified in available studies.

Cognitive and Neuroprotective Effects

Salk Institute work demonstrates that fisetin enhances long-term potentiation and memory formation in rodents, crosses the blood-brain barrier, and improves cognitive performance in multiple Alzheimer’s-disease mouse models. A new Phase 2 trial in mild Alzheimer’s disease (NCT07279714) launched in 2026. No published controlled cognitive-outcome data in humans exist as of January 2026.

Magnitude: Not quantified in available studies.

Metabolic Improvement

Rodent models of obesity and type 2 diabetes show that fisetin reduces body weight, improves glucose tolerance, and enhances insulin sensitivity, with mechanisms attributed to Nrf2 activation, SIRT1-mediated metabolic effects, and a 2025 study showing endothelial-cell senescence clearance improving metabolic dysfunction in obese mice (Suda et al., Cell Metabolism). No controlled human metabolic trials have been published.

Magnitude: Not quantified in available studies.

Speculative 🟨

Anticancer Effects

Extensive in vitro and animal evidence shows fisetin induces apoptosis in multiple cancer cell lines and reduces tumor growth in xenograft models of prostate, bladder, breast, head-and-neck, and colorectal cancers. Beyond the small colorectal-cancer adjunct trial, no controlled human trials of fisetin as an anticancer agent have reported efficacy data, and a Mayo Clinic Phase 1 program in glioma combining fisetin with dasatinib, quercetin, and temozolomide is in early stages.

Cardiovascular and Vascular Protection

Preclinical systematic reviews demonstrate fisetin protects against myocardial ischemia-reperfusion injury through antioxidant and anti-inflammatory mechanisms. A Phase 1/2 University of Colorado trial of fisetin in older adults with vascular dysfunction (NCT06133634) is active, and a Phase 2 trial in peripheral arterial disease (NCT06399809) is recruiting; both will be informative but no efficacy data are yet published.

Kidney Protection

A 2026 systematic review summarizes preclinical evidence for fisetin in drug-induced nephrotoxicity, diabetic nephropathy, and ischemic kidney injury, attributing benefits to suppression of inflammation, oxidative stress, and fibrotic signaling. No human kidney-outcome data exist.

Benefit-Modifying Factors

  • Genetic polymorphisms: Variations in CYP2C9 (a liver enzyme that metabolizes many drugs) and the UGT1A glucuronidation enzymes (phase II metabolic enzymes that conjugate flavonols for excretion) substantially affect fisetin’s metabolism and exposure. CYP2C9 poor metabolizers may achieve higher plasma levels at a given dose.

  • Baseline biomarker levels: Higher baseline systemic inflammation (high-sensitivity C-reactive protein, interleukin-6) or higher senescent-cell burden, as proxied by emerging blood markers such as the IL-23 receptor (Carver et al., Nature Aging, 2025), may predict greater senolytic and anti-inflammatory benefit. Individuals with already-low inflammatory burden may see smaller absolute changes.

  • Sex-based differences: The original 2018 study demonstrated senolytic effects in both male and female mice; the multi-site ITP found no lifespan extension in either sex. Sex-specific differences in flavonol pharmacokinetics in humans are not well characterized.

  • Pre-existing health conditions: The systematic review of fisetin in ischemia-reperfusion injury found that comorbidities such as diabetes and obesity blunt fisetin’s cardioprotective efficacy in animal models. Conversely, individuals with high inflammatory burden, frailty, or chronic disease may derive greater senolytic benefit, reflecting the rationale of ongoing trials in older adults and cancer survivors.

  • Age: Fisetin’s senolytic benefit in the original mouse study was demonstrable even when treatment began late in life (mouse-age equivalent of approximately 75 human years). Older individuals with higher senescent-cell burden are the explicit target population in most active human trials, though they also tend to have altered hepatic metabolism and polypharmacy that complicate response.

Potential Risks & Side Effects

A dedicated search across drug-reference sources, prescribing information for related flavonol-based products, and the published clinical-trial literature was performed to assemble the risk profile.

Low 🟥

Gastrointestinal Disturbance

Mild nausea, loose stools, diarrhea, and abdominal discomfort have been reported anecdotally with fisetin supplementation, particularly at the high single-day doses used in senolytic protocols. Published RCTs at 100 mg/day did not report significant gastrointestinal events, but the cumulative number of human subjects in published trials is small (under 250 across published RCTs).

Magnitude: Not quantified in available studies.

Drug-Interaction Risk via CYP Inhibition

Fisetin is a potent in vitro inhibitor of CYP2C9 and CYP2C19, two liver enzymes responsible for metabolizing several common medications (warfarin, phenytoin, glipizide, omeprazole) and the activation of clopidogrel (a platelet-inhibitor prodrug). This raises a theoretical and partly demonstrated risk of altered plasma levels of co-administered drugs and potentially of bleeding when combined with anticoagulants.

Magnitude: Not quantified in available studies.

Allergic and Dermatologic Reactions

Rare reports of itching, swelling, and rash have been associated with fisetin supplementation, mostly via supplement-adverse-event databases. Direct skin or respiratory exposure to the pure compound during manufacturing has been described as irritating.

Magnitude: Not quantified in available studies.

Speculative 🟨

Unknown Long-Term Safety at Supplemental Doses

No long-term human safety studies exist for fisetin at supplemental doses. Dietary intake is roughly 0.2–0.4 mg/day, while supplemental doses are typically 100–500 mg/day daily or 1,000–1,500 mg/day on the two-day “hit-and-run” senolytic protocol — several hundred to several thousand times higher than habitual food intake. Effects of chronic high-dose exposure on hormone, immune, or microbiome parameters remain unstudied.

Excessive Senescent-Cell Clearance

Senescent cells contribute negatively to age-related disease but also play roles in wound healing, tumor suppression, and tissue remodeling. Aggressive senolytic dosing could in principle impair these functions; this is a theoretical concern with no clinical signal in published human data.

Hormetic-Reversal at High Doses

A 2025 review (Calabrese et al., Biogerontology) argues that fisetin’s chemoprotective effects follow a biphasic dose-response in many model systems, with high doses losing or reversing benefit. This concept supports caution about escalating beyond evidence-based ranges.

Risk-Modifying Factors

  • Genetic polymorphisms: CYP2C9 poor metabolizers (approximately 1–3% of Northern European-descended populations carry two loss-of-function alleles) may accumulate higher fisetin levels at a given dose, potentially amplifying both benefits and side effects. Genotyping is available and may be informative for individuals on warfarin or other CYP2C9-sensitive medications.

  • Baseline biomarker levels: Individuals with thrombocytopenia (low platelet count) or impaired coagulation are at theoretically elevated risk given fisetin’s CYP2C9 inhibition and possible antiplatelet activity.

  • Sex-based differences: No sex-specific risk differences have been established for fisetin in humans, though some CYP2C9 substrates show modest sex differences in clearance.

  • Pre-existing health conditions: Individuals with bleeding disorders, those receiving anticoagulant or antiplatelet therapy, those with hepatic impairment (Child-Pugh Class B or C, classifications of cirrhosis severity), or those with active gastrointestinal bleeding face elevated risk. Pregnancy and lactation are practical contraindications because of the absence of safety data.

  • Age: Older adults more often have reduced hepatic enzyme activity, polypharmacy, and concurrent antiplatelet use, all of which raise the probability of clinically significant interactions.

Key Interactions & Contraindications

  • Anticoagulants (warfarin, dabigatran, apixaban, rivaroxaban, edoxaban): Caution. Fisetin’s potent CYP2C9 inhibition can in principle raise warfarin exposure and bleeding risk; effects on direct oral anticoagulants are less well characterized but pharmacokinetic interaction is possible. Monitor international normalized ratio (INR, a measure of how long blood takes to clot) within 1–2 weeks of starting.

  • Antiplatelet drugs (aspirin, clopidogrel, ticagrelor, prasugrel): Caution. Additive bleeding risk; CYP2C19 inhibition by fisetin may also reduce clopidogrel activation and effectiveness.

  • Other CYP2C9 substrates (phenytoin, glipizide, celecoxib, losartan): Monitor. Fisetin co-administration may increase plasma levels.

  • Other CYP2C19 substrates (omeprazole, esomeprazole, lansoprazole, citalopram, escitalopram, voriconazole): Monitor.

  • Chemotherapy agents: Caution. The colorectal-cancer RCT used fisetin alongside chemotherapy without overt safety problems, but effects on chemotherapy pharmacokinetics are not characterized for most agents. Coordinate with oncology before combining.

  • Other senolytics and high-dose flavonoids (dasatinib + quercetin combination, luteolin, kaempferol): Caution. Mechanistic overlap can amplify effects and shared CYP-inhibition can alter co-medication exposure; ongoing Mayo Clinic glioma protocol intentionally combines fisetin with dasatinib and quercetin under medical supervision.

  • Populations who should avoid fisetin: Pregnant or breastfeeding women (no safety data); patients with active bleeding or recent (<30 days) gastrointestinal bleed; patients within two weeks of a planned major surgical procedure; patients with severe hepatic impairment (Child-Pugh Class C); patients on warfarin without coordinated INR monitoring.

Risk Mitigation Strategies

  • Start at the lowest effective dose: Begin daily supplementation at 100 mg/day and increase only if tolerated and clinically justified, in keeping with the published RCT dosing and the hormetic-reversal concern at high doses.

  • Take with a fat-containing meal: Fisetin’s poor aqueous solubility means absorption increases meaningfully when co-ingested with dietary fat (e.g., olive oil, avocado, nuts), which both improves bioavailability and reduces gastrointestinal irritation.

  • Coordinate with anticoagulant and antiplatelet therapy: For patients on warfarin, obtain a baseline INR, recheck at 1–2 weeks after starting fisetin, and recheck periodically; for patients on direct oral anticoagulants or antiplatelets, discuss with the prescribing clinician before initiating, given the absence of formal interaction studies.

  • Stop fisetin at least 2 weeks before elective surgery: Mitigates theoretical bleeding risk from CYP2C9 inhibition and possible antiplatelet activity around the perioperative window.

  • Use intermittent (“hit-and-run”) dosing for senolytic intent: When the goal is senescent-cell clearance, two consecutive days every 1–2 months mirrors the protocol used in mouse work and at Mayo Clinic, limiting cumulative exposure and reducing concern about chronic high-dose effects.

  • Monitor for unusual bruising or bleeding in the first 4 weeks: Especially in older adults and those on concurrent antiplatelet or anticoagulant therapy; new bruising, gum bleeding, or melena (dark, tarry stools indicating gastrointestinal bleeding) warrants discontinuation and clinical review.

  • Verify formulation and source: Use products with a third-party certificate of analysis to mitigate adulteration and impurity risk that could otherwise drive non-fisetin adverse events.

Therapeutic Protocol

The most cited protocol derives from the Mayo Clinic clinical-trial program led by James Kirkland and colleagues. Two principal patterns are used: an intermittent high-dose protocol intended for senolytic effect and a continuous low-dose protocol used in some inflammation- and neuroprotection-oriented work. Practitioners differ on which pattern to adopt for general health and longevity purposes; both are described below without framing one as the default.

  • Intermittent senolytic protocol: 20 mg/kg body weight (approximately 1,400 mg for a 70 kg person) taken orally for two consecutive days, repeated every 1–2 months. Mirrors the Mayo Clinic trial protocol and the hit-and-run mouse studies and is associated with the most direct evidence for senescent-cell clearance.

  • Continuous low-dose protocol: 100–500 mg/day taken with a fat-containing meal. Anchored at 100 mg/day by the published colorectal-cancer and stroke RCTs and by the doses used in the Examine and Life Extension consumer-oriented overviews; higher daily doses lack controlled human evidence.

  • Best time of day: No specific time-of-day data exist. Taking with the largest fat-containing meal is the standard recommendation given the lipophilic profile and short plasma half-life of unformulated material.

  • Half-life: Approximately 1–2 hours in humans for unformulated fisetin, with plasma levels generally undetectable beyond 2–4 hours post-ingestion. Bioavailability-enhanced formulations (e.g., fenugreek galactomannan-based, liposomal) report substantially extended exposure.

  • Single versus split doses: For the intermittent protocol, the daily dose is most often taken as a single dose with food or split into morning and evening doses on each treatment day. For the continuous protocol, a single daily dose with a fat-containing meal is the standard pattern.

  • Genetic considerations: CYP2C9 poor metabolizers may achieve higher exposure at a given dose; no validated pharmacogenomic dosing rules exist, but starting at the lower end of the daily range is reasonable in known poor metabolizers.

  • Sex-based differences: No sex-specific dosing rules have been validated. The Mayo Clinic frailty trial program enrolls women specifically (NCT03430037, AFFIRM), reflecting interest in post-menopausal frailty rather than sex-differential dosing.

  • Age considerations: Senolytic rationale is strongest in older adults with higher senescent-cell burden, and current human trials predominantly enroll adults aged 65 and older. Older adults should be more cautious about drug interactions due to higher background polypharmacy.

  • Baseline biomarker levels: Higher baseline high-sensitivity C-reactive protein and interleukin-6 may indicate greater room for senolytic benefit; emerging blood-based senescence biomarkers are not yet validated for routine pre-treatment selection.

  • Pre-existing health conditions: Adults with frailty, sarcopenia (age-related loss of muscle mass and strength), post-cancer fatigue, or chronic inflammatory disease are the populations most directly studied; those with severe hepatic impairment or active bleeding are not appropriate candidates without medical oversight.

Discontinuation & Cycling

  • Duration of use: The intermittent senolytic protocol is inherently periodic — every 1–2 months by design — and is typically envisioned as an indefinite, long-horizon practice rather than a defined treatment course. The continuous low-dose protocol has no consensus duration in the absence of long-term human data.

  • Withdrawal effects: No withdrawal effects have been reported or are mechanistically expected, given the short half-life and absence of receptor-based dependence.

  • Tapering: No taper is required; the short plasma half-life means fisetin clears rapidly upon discontinuation.

  • Cycling: Cycling is built into the senolytic protocol by design (two days on, then weeks off). For continuous low-dose use, some practitioners apply intermittent breaks (for example, three weeks on / one week off) on the rationale of avoiding desensitization, although no clinical evidence supports any specific cycling schedule.

Sourcing and Quality

  • Formulation matters: Standard unformulated fisetin has poor oral bioavailability with a 1–2 hour plasma half-life. Bioavailability-enhanced formulations using fenugreek-derived galactomannans (commonly branded Bio-Fisetin) or liposomal carriers have been reported to deliver substantially higher and more sustained plasma levels, which is the basis for using lower per-dose amounts in some products.

  • Purity and certificate of analysis: Reputable products provide third-party certificate-of-analysis documentation specifying the fisetin content, identity confirmation, and limits for heavy metals, residual solvents, and microbial contamination. Source materials are usually plant extracts of Cotinus coggygria or Rhus succedanea, or pharmaceutical-grade synthetic fisetin.

  • Third-party testing: ConsumerLab has not published a comprehensive product-test review of fisetin comparable to its tests of quercetin or vitamin D. Look for independent verification through NSF International, USP, ConsumerLab, or Informed Choice/Sport when available.

  • Reputable brands and formulations: Life Extension (Bio-Fisetin), Doctor’s Best (Novusetin branded extract), Swanson, Pure Encapsulations, and Thorne are among the more frequently mentioned producers. Branded ingredients that appear repeatedly in published commentary include Novusetin (from Natural Remedies) and Cognisetin.

  • Storage: Fisetin is light-sensitive; storage in a cool, dry, dark place, in opaque packaging, preserves potency.

Practical Considerations

  • Time to effect: For the senolytic mechanism, the cellular event (apoptosis of senescent cells) is rapid, occurring during and shortly after a treatment window, but downstream functional effects (reduced inflammation, improved physical function) are expected to emerge over weeks to months. For anti-inflammatory and neuroprotective use at continuous low doses, several weeks of consistent use are typically reported before changes in inflammatory markers or subjective measures appear.

  • Common pitfalls:

    • Taking unformulated fisetin without dietary fat, dramatically reducing already-poor absorption.

    • Treating senolytic mouse data and dietary doses as interchangeable; single-day senolytic protocols use orders-of-magnitude higher doses than dietary intake.

    • Combining fisetin with anticoagulants or antiplatelet agents without informing the prescribing clinician.

    • Extrapolating one-laboratory mouse lifespan results to humans without weighing the failed multi-site replication.

  • Regulatory status: Fisetin is sold as a dietary supplement in the United States and is not approved by the U.S. Food and Drug Administration for any medical indication. Its use in human trials at major academic centers is conducted under investigational new drug applications.

  • Cost and accessibility: Daily fisetin supplements typically cost USD 15–45 for a 30-day supply, depending on formulation, with bioavailability-enhanced formulations toward the upper end. Higher-dose senolytic protocols (1–1.5 g doses) require either combining multiple capsules or buying bulk powder; gram quantities cost roughly USD 0.50–2.00 per gram in bulk. Availability is broad through online supplement retailers.

Interaction with Foundational Habits

  • Sleep: No direct evidence that fisetin disrupts or improves sleep at typical doses. A trial combining fisetin with urolithin A (NCT06990256) lists sleep quality and aging biomarkers among its outcomes; results are not yet available. Until then, no specific timing recommendation around sleep is supported.

  • Nutrition: Fisetin is fat-soluble and absorption is meaningfully potentiated by a fat-containing meal (direct interaction; mechanism is improved micellar solubilization in the gut). Whole-food sources (strawberries, apples, persimmons) contribute negligible amounts compared with supplemental doses. Polyphenol-rich diets may complement fisetin’s antioxidant and anti-inflammatory pathways through overlapping NF-κB and Nrf2 effects.

  • Exercise: No direct evidence that fisetin blunts exercise-induced adaptations, in contrast to concerns raised for some high-dose isolated antioxidants; the short half-life and intermittent dosing make exercise-blunting interaction unlikely on theoretical grounds. Several active trials (NCT06113016, NCT05595499) intentionally pair fisetin with exercise programs in cancer-survivor populations.

  • Stress management: Indirect interaction. Fisetin’s activation of SIRT1 and Nrf2 overlaps mechanistically with the body’s endogenous stress-response systems and inflammatory regulation; no clinical data link fisetin to cortisol modulation or measured stress-resilience outcomes in humans, so the practical implication is minimal at present.

Monitoring Protocol & Defining Success

Baseline laboratory testing is appropriate before starting fisetin to characterize inflammatory burden, hepatic and renal function, and coagulation status, and to set reference points for measuring response.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
High-sensitivity C-reactive protein (hs-CRP) < 1.0 mg/L Systemic inflammation; primary biomarker target of fisetin’s anti-inflammatory effect Fasting preferred; conventional reference range <3.0 mg/L; values >3.0 indicate higher baseline inflammation
Interleukin-6 (IL-6) < 1.5 pg/mL Pro-inflammatory cytokine; component of senescence-associated secretory phenotype More sensitive than hs-CRP for low-grade chronic inflammation; conventional range <5.0 pg/mL
CBC with differential Within standard laboratory range Baseline immune-cell and platelet status CBC = complete blood count; platelet count especially relevant given potential antiplatelet effect
INR 0.9–1.1 (off anticoagulants) Coagulation baseline INR = international normalized ratio; essential for patients on warfarin; recheck 1–2 weeks after starting fisetin
CMP Within standard laboratory range Baseline liver and kidney function CMP = comprehensive metabolic panel; includes ALT, AST (liver enzymes), creatinine, blood urea nitrogen, and estimated glomerular filtration rate (a calculated kidney-function index)
Fasting glucose 72–85 mg/dL Metabolic health baseline Conventional range 70–100 mg/dL; preclinical metabolic-improvement signal motivates monitoring
HbA1c 4.8–5.2% 3-month average glucose HbA1c = hemoglobin A1c; conventional range <5.7%; recheck at 3-month intervals
Lipid panel LDL-C < 100 mg/dL; HDL > 50 mg/dL Cardiovascular risk baseline LDL = low-density lipoprotein cholesterol; HDL = high-density lipoprotein cholesterol; fisetin’s cardiovascular signal is preclinical; lipids are part of routine longevity panel

Ongoing monitoring is suggested at 4 weeks for early tolerance and any unusual bruising or bleeding (clinical check, no labs required), at 3 months for repeat hs-CRP and IL-6 to assess inflammatory response, at 6 months for repeat comprehensive metabolic panel and complete blood count to assess hepatic, renal, and hematologic safety, and annually for the full baseline panel. For patients on warfarin, INR is checked within 1–2 weeks of initiation and periodically thereafter.

Qualitative markers help capture effects that laboratory tests miss:

  • Energy and overall vitality

  • Cognitive clarity and short-term memory (subjective)

  • Joint comfort, mobility, and walking ease

  • Recovery from illness, exertion, or stress

  • Skin appearance and wound healing

Emerging Research

A landmark replication finding deserves continued attention:

Several active human trials are likely to shape the evidence base in 2026 and beyond:

  • Vascular function in older adults: NCT06133634 — Phase 1/2 trial, 70 participants, University of Colorado Boulder, evaluating effects on endothelial function and arterial stiffness; active, not recruiting.

  • Peripheral arterial disease: NCT06399809 — Phase 2 trial in PAD (peripheral arterial disease), 34 participants, Northwestern University; recruiting.

  • Healthy aging: NCT07195318 — 120 participants, evaluating fisetin in healthy older adults; recruiting.

  • Multimorbidity pilot: NCT06431932 — Phase 1/2 pilot in healthy volunteers and older patients with multimorbidity, 60 participants; recruiting.

  • Breast cancer survivors – physical function: NCT05595499 — Phase 2 trial in Stage I–III breast cancer survivors, 88 participants, Jonsson Comprehensive Cancer Center; recruiting.

  • Breast cancer survivors – frailty prevention: NCT06113016 — Phase 2 trial pairing fisetin with exercise, 164 participants; recruiting.

  • Cancer-survivor fatigue: NCT06819254 — pilot in older cancer survivors, 60 participants, Wake Forest; recruiting.

  • Mild Alzheimer’s disease: NCT07279714 — Phase 2 trial, 5 participants in pilot phase, Sunnybrook Health Sciences Centre; recruiting.

  • Glioma combination senolytics: NCT07025226 — Early Phase 1 of sequential or combined senolytics (dasatinib, quercetin, fisetin) with temozolomide, 10 participants, Mayo Clinic; recruiting.

Additional emerging directions include:

Conclusion

Fisetin holds an unusual position in the longevity-supplement landscape. It has one of the most striking preclinical senolytic profiles of any natural compound and a coherent biological story that links senescent-cell clearance, anti-inflammatory action, and neuroprotection. At the same time, the human evidence base remains thin, and a multi-site replication of the original mouse lifespan finding did not reproduce that result, introducing real uncertainty about the durability of the original signal.

Two small human trials — in cancer chemotherapy and in acute stroke care — offer early evidence that fisetin can lower inflammatory markers in narrowly defined situations. Much of the broader research is concentrated at institutions and commercial vendors with direct financial or reputational interests in fisetin’s characterization: Mayo Clinic and the Salk Institute hold senolytic-related intellectual property and run the principal trials, and consumer publications such as Life Extension simultaneously sell branded fisetin products — a structural bias to keep in mind when weighing the evidence on either side.

For a longevity-oriented audience, the realistic picture is one of uncertain but plausible benefit, modest and largely manageable risk dominated by drug-interaction concerns through liver-enzyme inhibition, and an actively contested evidence base. The interpretation is best held with curiosity and discipline rather than committed enthusiasm in either direction, with attention to formulation quality, sensible dosing, and coordination with any concurrent medication regimens.

Top - Benefits - Risks - Protocol